Tag: covid19

Improving healthcare, but for whom? Studying the International Finance Corporation’s investments in health

A new study by Wemos shows the need for the International Finance Corporation (IFC) to increase its focus on health equity, ensuring that their private investments in healthcare promote equitable and universal access. As the private sector arm of the World Bank Group, the IFC is a major development actor. Between 2017 and 2021, their investments in health increased. They focus on improving quality and availability of health services and products, but almost never consider whether everyone can access them. Only one of the 88 IFC projects in health in this period mentions equitable access as an expected development impact.

Continue reading

Wemos and Pharmaceutical Accountability Foundation proud recipients of National Postcode Lottery donation

Wemos and the Pharmaceutical Accountability Foundation are proud and pleased to receive a donation of 500,000 euros from the Dutch National Postcode Lottery. With this support, we commit to improving access to affordable vaccines and medicines for everyone. We strive for a world in which everyone’s health takes precedence over commercial interests. Our goal is to change the system so that prices are set fairly and monopolies do not stand in the way of the availability of vaccines and medicines. We also want to see conditions attached when taxpayers’ money is invested in medicines development, and want pharmaceutical companies to fulfil their duty of care. This way we contribute to a world that is well prepared for health threats such as pandemics, now and in the future.

Continue reading

New website provides overview and review of initiatives for access to medical products against Covid-19

Wemos has launched covid19response.org, a website that provides an up-to-date overview of international initiatives by public institutions to enhance access to medical products against Covid-19, such as vaccines, medicines and diagnostics. It presents their characteristics and reviews their potential to contribute to an equitable and effective response to the current and future pandemics, as well as the support they need to become successful. Among the assessed initiatives are COVAX, the TRIPS Waiver and the South African mRNA hub.

Continue reading

Milestone: research institute shares patents and know-how globally through C-TAP

Wemos is delighted that the Spanish National Research Council (CSIC) shares its intellectual property and know-how for the production of its Covid-19 diagnostic tool with the Covid-19 Technology Access Pool (C-TAP) of the World Health Organization (WHO). As such, CSIC permits all qualified manufacturers worldwide to make the product and distribute it to any country in the world, royalty-free for low- and middle-income countries. This is the first global, non-exclusive license for a Covid-19 innovation and thus a milestone for equal access to medical products.

Continue reading

Pfizer’s knowledge sharing on antiviral is positive step, but more is needed

The US pharmaceutical company Pfizer will share its intellectual property and know-how for the production of its Covid-19 pill in the Medicines Patent Pool (MPP). The company is following the example of Merck & Co (MSD) that recently announced the same. This is an important step in the right direction to enhance global access to medical products against Covid-19. Wemos is calling on Pfizer and other vaccine makers to do the same for their vaccines.

Continue reading

Breakthrough: Merck will share intellectual property and know-how for Covid-19 pill

Today US pharmaceutical company Merck & Co (trade name MSD) announced that it will share its intellectual property and know-how with the Medicines Patent Pool (MPP) for the production of its Covid-19 pill. This is a major breakthrough in the quest for access to medical products against Covid-19. If the authorities approve this product, the MPP can grant sublicenses to other pharmaceutical companies so they too can produce the antiviral treatment. This will give 105 low- and middle-income countries accelerated access to this drug.

Continue reading

ACT-A: put words into action to combat Covid-19

ACT-A, the global collaboration to respond to the Covid-19 pandemic, can and must do more to effectively combat this international health crisis. It must use its leverage to significantly improve equitable access to vaccines, therapeutics and diagnostics, and establish adequate funding of health systems in order to implement these commodities. Wemos fully supports the urgent recommendations on these matters of the Platform for Civil Society and Community Representatives to ACT-A. Also, we are proud that our global health advocate Amanda Banda was selected to be civil society representative to ACT-A’s Health Systems Connector.

Continue reading